Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase

British Journal of Cancer

Volumn 80, Issue 8, 1999, Pages 1223-1230

  Wang, X ^a,b   Doherty, G P ^a,b   Leith, M K ^a,b   Curphey, T J ^c   Begleiter, A ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

Cytotoxicity; Dt diaphorase; Enzyme inducers; Mitomycin C

Indexed keywords

1,2 DITHIOLE 3 THIONE DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; GALLIC ACID PROPYL ESTER; MALEIC ACID; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; BONE MARROW CELL; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; STOMACH CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; CELL DEATH; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; HUMANS; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); TUMOR CELLS, CULTURED;

EID: 0033020796     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690489     Document Type: Article

References (57)

1. Adams GE and Stratford IJ (1994) Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys 29: 231-238
2. Appelt LC and Reicks MM (1997) Soy feeding induces phase II enzymes in rat tissues. Nutr Cancer 28: 270-275
3. Barham HM, Inglis R, Chinje EC and Stratford IJ (1996) Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells. Br J Cancer 74: 1188-1193
4. Beall HD, Murphey AM, Siegel D, Hargreaves RH, Butler J and Ross D (1995) Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumour quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48: 499-504
5. Beall HD, Liu YF, Siegel D, Bolton EM, Gibson NW and Ross D (1996) Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 51: 645-652
6. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J and von Roemeling R (1997) Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 8: 363-367
7. Begleiter A, Robotham E, Lacey G and Leith MK (1989) Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett 45: 173-176
8. Begleiter A, Robotham E and Leith MK (1992) The role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia. Mol Pharmacol 41: 677-683
9. Begleiter A, Verburg L, Ashique A, Lee K, Israels LG, Mowat MRA and Johnston JB (1995) Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 9: 1875-1881
10. Begleiter A, Leith MK and Curphey TJ (1996) Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Br J Cancer 74: S9-S14
11. Belcourt MF, Hodnick WF, Rockwell S and Sartorelli AC (1996) Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome C (P450) reductase. Proc Natl Acad Sci USA 93: 456-460
12. Belinsky M and Jaiswal AL (1993) NAD(P)H:quinone oxidoreductase I (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12: 103-117
13. Beyer RE, Segura Aguilar JE and Ernster L (1988) The anticancer enzyme DT diaphorase is induced selectively in liver during ascites hepatoma growth. Anticancer Res 8: 233-238
14. Boyer MJ (1997) Bioreductive agents: a clinical update. Oncol Res 9: 391-395
15. Coia LR (1993) The use of mitomycin in esophageal cancer. Oncology 50: 53-62
16. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS and Catton CN (1993) Mitomycin in anal canal carcinoma. Oncology 50: 63-69
17. Doherty GP, Leith MK, Wang X, Curphey TJ and Begleiter A (1998) Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents. Br J Cancer 77: 1241-1252
18. Egner PA, Kensler TW, Prestera T, Talalay P, Libby AH, Joyner HH and Curphey TJ (1994) Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis 15: 177-181
19. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269
20. Fujita K, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, Kumai K and Kitajima M (1998) Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer. Anticancer Res 18: 1973-1978
21. Gustafson DL and Pritsos CA (1992) Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. J Natl Cancer Inst 84: 1180-1185
22. Habig WH, Pabst MJ and Jakoby WB (1974) Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139
23. Hodnick WF and Sartorelli AC (1993) Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res 53: 4907-4912
24. Hortobagyi GN (1993) Mitomycin: its evolving role in the treatment of breast cancer. Oncology 50: 1-8
25. Jaiswal AK (1991) Human NAD(P)H:quinone oxidoreductase (NQO 1) gene structure and induction by dioxin. Biochemistry 30: 10647-10653
26. Jaiswal AK, Burnett P, Adesnik M and McBride OW (1990) Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 29: 1899-1906
27. Johnston JB, Verburg L, Shore T, Williams M, Israels LG and Begleiter A (1994) Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8: S140-S143
28. Kensler TW and Helzlsouer KJ (1995) Oltipraz: clinical opportunities for cancer chemoprevention. J Cell Biochem Suppl. 22: 101-107
29. Kirkpatrick DL, Duke M and Goh TS (1990) Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res 14: 459-466
30. Lown JW, Begleiter A, Johnson D and Morgan AR (1976) Studies related to antitumor antibiotics. Part V. Reaction of mitomycin C with DNA examined by ethidium fluorescence assay. Can J Biochem 54: 110-119
31. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oic HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD and Ross D (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52: 4752-4757
32. Manson MM, Ball HW, Barrett MC, Clark HL, Judah DJ, Williamson G and Neal GE (1997) Mechanism of action of dietary chemoprotective agents in rat liver: induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism. Carcinogenesis 18: 1729-1738
33. Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA and Bello J (1997) DT-diaphorase and cytochrome b, reductase in human lung and breast tumours. Br J Cancer 76: 923-929
34. Marshall RS and Rauth AM (1986) Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair deficient mutant. Cancer Res 46: 2709-2713
35. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T and Tsuruo T (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 56: 2823-2826
36. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R and Kris MG (1997) Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non small cell lung cancer. Ann Oncol 8: 1269-1271
37. Nishiyama M, Saeki S, Aogi K, Hirabayashi N and Toge T (1993) Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: differences in in vitro and in vivo systems. Int J Cancer 53: 1013-1016
38. Nishiyama M, Suzuki K, Kumazaki T, Yamamoto W, Toge T, Okamura T and Kurisu K (1997) Molecular targeting of mitomycin C chemotherapy. Int J Cancer 72: 649-656
39. Plumb JA, Gerritsen M, Milroy R, Thomson P and Workman P (1994) Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys 29: 295-299
40. Prestera T, Holtzelaw WD, Zhang Y and Talalay P (1993) Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA 90: 2965-2969
41. Pritsos CA and Sartorelli AC (1986) Generation of reactive oxygen radicals through bioactivation of mitomycin C antibiotics. Cancer Res 46: 3528-3532
42. Prochaska HJ and Santamaria AB (1988) Direct measurement of NAD(P)H:quinone reductase from cells cultured in microliter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 169: 328-336
43. Riley RJ and Workman P (1992) DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43: 1657-1669
44. Rockwell S, Sartorelli AC, Tomasz M and Kennedy KA (1993) Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev 12: 165-176
45. Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT and Gibson NW (1993) DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev 12: 83-101
46. Ross D, Beall H, Travel RD, Siegel D, Phillips RM and Gibson NW (1994) Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 6: 493-500
47. Schellens JHM, Planting AST, Van Acker BAC, Loos WJ, De Boer-Dennert M, Van der Burg MEL, Koier I, Krediet RT, Stoter G and Verweij J (1994) Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 86: 906-912
48. Schlager JJ and Powis G (1990) Cytosolic NAD(P)H: (quinone acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45: 403-409
49. Smitskamp-Wilms E, Giaccone G, Pinedo HM, Van der Laan BFAM and Peters GJ (1995) DT diaphorase activity in normal and neoplastic human tissues: an indicator of sensitivity to bioreductive agents? Br J Cancer 72: 917-921
50. Spain RC (1993) The case for mitomycin in non-small cell lung cancer. Oncology 50: 35-52
51. Strobel HW and Dignam JD (1978) Purification and properties of NADPH cytochrome P-450 reductase. Methods Enzymol 52: 89-96
52. Tomasz M, Lipman R, Chowdary D, Pawlak L, Verdine GL and Nakanishi K (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235: 1204-1208
53. Wang W and Higuchi CM (1995) Induction of NAD(P)H:quinone reductase by vitamins A, E, and C in Colo205 cancer cells. Cancer Lett 98: 63-69
54. Winski SL, Hargreaves RHJ, Butler J and Ross D (1998) New aziridinylbenzoquinones as NAD(P)H:quinone oxidoreductase (NQO 1)-directed antitumor agents. Proc Am J Assoc Cancer Res 29: 303
55. Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12: 73-82
56. Xu BH, Gupta V and Singh SV (1994) Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer 58: 686-692
57. Zhang Y, Kensler TW, Cho CG, Posner GH and Talalay P (1994) Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147-3150